Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer

Journal of Clinical Oncology

Volumn 32, Issue 13, 2014, Pages 1309-1316

  Stockler, Martin R ^a   Hilpert, Felix ^c   Friedlander, Michael ^b   King, Madeleine T ^a   Wenzel, Lari ^e   Lee, Chee Khoon ^a   Joly, Florence ^f   De Gregorio, Nikolaus ^d   Arranz, José Angel ^h   Mirza, Mansoor Raza ⁱ   Sorio, Roberto ^j   Freudensprung, Ulrich ^k   Sneller, Vesna ^k   Hales, Gill ^k   Pujade Lauraine, Eric ^g  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CENTRE FRANÇOIS BACLESSE   (France)

^g Section of Radiology   (France)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ Rigshospitalet   (Denmark)

^j CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^k F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE OVARIAN CANCER MODULE 28; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG RESISTANCE; MIDDLE AGED; MULTICENTER STUDY; OVARY TUMOR; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; SELF REPORT; TOPOTECAN; TREATMENT OUTCOME;

EID: 84902685820     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.4240     Document Type: Article

References (13)

1. Naumann RW, Coleman RL: Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 71:1397-1412, 2011
2. Friedlander M, Butow P, Stockler M, et al: Symptom control in patients with recurrent ovarian cancer: Measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. Int J Gynecol Cancer 19:S44-S48, 2009 (suppl 2)
3. Pujade-Lauraine E, Hilpert F, Weber B, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302-1308, 2014
4. Friedlander M, Trimble E, Tinker A, et al: Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 21:771-775, 2011
5. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993 (Pubitemid 23073154)
6. Greimel E, Bottomley A, Cull A, et al: An international field study of the reliability and validity of a diseasespecific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 39:1402-1408, 2003 (Pubitemid 36773783)
7. Beaumont J, Yount S, Lalla D, et al: Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a phase II clinical trial of pertuzumab in patients with advanced ovarian cancer. J Clin Oncol 25:663s, 2007 (suppl; abstr 16021)
8. Luckett T, King M, Butow P, et al: Assessing health-related quality of life in gynecologic oncology: A systematic review of questionnaires and their ability to detect clinically important differences and change. Int J Gynecol Cancer 20:664-684, 2010
9. Cella D, Paul D, Yount S, et al: What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 21:526-535, 2003 (Pubitemid 37169556)
10. Osoba D, Bezjak A, Brundage M, et al: Analysis and interpretation of health-related quality-oflife data from clinical trials: Basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41:280-287, 2005 (Pubitemid 40126961)
11. Brundage M, Osoba D, Bezjak A, et al: Lessons learned in the assessment of health-related quality of life: Selected examples from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:5078-5081, 2007 (Pubitemid 350232286)
12. Sloan JA, Dueck AC, Erickson PA, et al: Analysis and interpretation of results based on patientreported outcomes. Value Health 10:S106-S115, 2007 (suppl 2)
13. Siddiqui O: MMRM versus MI in dealing with missing data: A comparison based on 25 NDA data sets. J Biopharm Stat 21:423-436, 2011